Pharmaceutical manufacturer Eli Lilly has filed a significant civil lawsuit in U.S. District Court, accusing a Florida-based mail-order pharmacy and several high-profile religious leaders of orchestrating a massive $200 million rebate fraud operation. The legal action centers on DrugPlace, a pharmacy allegedly working in tandem with the Community Health Initiative, an organization linked to the Church of God in Christ. While the church institution is not a defendant, the lawsuit names several prominent bishops and leaders as key figures in the alleged scheme.

The complaint details a dual-profit strategy where the defendants reportedly purchased large volumes of the diabetes medication Trulicity through legitimate channels before reselling the drugs on the secondary market. Simultaneously, the pharmacy allegedly submitted falsified rebate claims to Eli Lilly, claiming the medication was dispensed to church members. The manufacturer asserts that many of these patients were either fabricated or could not be verified, and the volume of claims far exceeded the realistic needs of the church’s actual membership base.

Eli Lilly identified the irregularities in 2025 through internal data analysis, which flagged suspicious patterns such as uniform prescription quantities and a complete absence of standard refill behavior. The company is now seeking immediate legal intervention, including a temporary restraining order and a preliminary injunction, to stop the activity. The filing notes that DrugPlace began liquidating assets shortly after the internal investigation surfaced. Among the individuals named in the suit are Readus C. Smith III, Bishop Jerry Maynard Sr., Jerry Maynard II, Misha Maynard, and pharmacy executives Paul Joshua Leight and Kevin Michael Singer.

Key Takeaways

• Eli Lilly is suing DrugPlace and several Church of God in Christ leaders for an alleged $200 million rebate fraud scheme.
• The scheme involved double-dipping by reselling Trulicity on the secondary market while simultaneously filing fake rebate claims.
• The manufacturer discovered the fraud through data analysis that revealed statistically impossible prescription patterns and non-existent patient records.

Editor’s Analysis & Impact

This lawsuit highlights a growing vulnerability in pharmaceutical supply chains: the exploitation of rebate programs through secondary market arbitrage. By targeting high-volume medications like Trulicity, bad actors can create significant financial leakage that impacts both manufacturer margins and the integrity of patient access programs. The involvement of religious organizations as a front for these activities adds a complex layer of reputational risk and suggests a sophisticated attempt to mask fraudulent claims within legitimate community health initiatives. As manufacturers increasingly rely on data analytics to police their distribution networks, we expect to see a surge in similar litigation. The rapid liquidation of assets by the pharmacy defendant underscores the urgency of these legal actions, as companies scramble to recover funds before entities dissolve to avoid liability.

Frequently Asked Questions

Q: What specific medication is at the center of the fraud allegations?
A: The lawsuit centers on the diabetes medication Trulicity, which was allegedly purchased and resold on the secondary market while fraudulent rebate claims were filed.

Q: How did Eli Lilly discover the alleged fraud?
A: The company uncovered the scheme in 2025 using data analysis that identified suspicious patterns, such as identical prescription quantities and a lack of standard refill activity among the listed patients.